article thumbnail

Tackling immune-mediated disease with CAR Tregs

European Pharmaceutical Review

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

article thumbnail

Not Just for Kids: The Case for Modernizing Immunization Registries

Fierce Healthcare

Not Just for Kids: The Case for Modernizing Immunization Registries. Wed, 12/07/2022 - 16:20.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ASH: With immune thrombocytopenia win, argenx proves efgartigimod’s no one-trick pony in autoimmune disease

Fierce Pharma

ASH: With immune thrombocytopenia win, argenx proves efgartigimod’s no one-trick pony in autoimmune disease. Sat, 12/10/2022 - 09:12. fkansteiner.

article thumbnail

2022 CVS Health Minority Scholarship For Pharmacy Students Winners Announced

Pharmacy Is Right For Me

We’re thrilled to announce the winners of the 2022 CVS Health Minority Scholarship for Pharmacy Students! The 2022 CVS Health Minority Scholarship for Pharmacy Students winners We connected with each of the 2022 scholarship awardees to discuss how this scholarship will help them move forward in pursuing a career in pharmacy.

article thumbnail

Pharmacy Focus: Move the Needle Monday- The 2022-23 Flu Season and What to Expect

Pharmacy Times

Keeping up with the latest immunizations and being prepared for this year's flu season is essential to staying on top of your health.

article thumbnail

ESMO 2022: the evolution of TIL therapy – a highly promising approach

Pharmaceutical Technology

Before TIL infusion, the patient undergoes lymphodepletion, which reduces the proportion of myeloid immune suppressive cells and creates space for the incoming lymphocytes. The high level of neoantigens in melanoma makes this the ideal setting for TIL therapy, with tumours often containing multiple clones of tumour-reactive immune cells.

article thumbnail

Summer 2022 haemophilia trial update

European Pharmaceutical Review

Some people with haemophilia may also develop inhibitors, antibodies that are an immune response to the clotting factors in replacement therapy that cause the treatment to stop working. Dosing in the Phase III study is expected to start in the fourth quarter of 2022. Novo Nordisk – concizumab and Mim8. compared to 11.8